New features correction of the dyslipidemia in patients with diabetes mellitus and metabolic cardiovascular risk factors
DOI:
https://doi.org/10.14739/2409-2932.2014.1.24831Keywords:
cardiovascular diseases, dyslipidemia, treatment, pitavastatinAbstract
The prospects of using new drug of statine class – pitavastatine – in the prophylaxis and treatment of cardiovascular diseases have
been considered in this review. The data of international іnvestigations on the comparative effi cacy of pitavastatine have been given; its pleiotropic effects, high profi le safety and tolerance, the decrease in the risk of drugs’ interaction have been shown.
References
Arrigo F.G. Cicero From risk factor assessment to cardiovascular disease risk and mortality modification: the first 40 years of the Brisighella Heart Study / Arrigo F.G. Cicero, Ada Dormi, Sergio D’Addato, Claudio Borghi // Clinical Lipidology. – 2011. – Vol. 6. – № 3. – Р. 269–276.
Catapano A.L. Pitavastatin: a different pharmacological profile / A.L. Catapano // From Clinical Lipidology. – 2012. – V. 7. – № 3. – P. 3–9.
Chapman M.J. Pitavastatin: a new option for the reduction of cardiovascular risk factors. (Poster-Abstract) / M.J. Chapman, J.J.P. Kastelein // Clinical Lipidology. –2012. – V. 7. – № 3. – Suppl. 1.
Claudio Borghi. Which statin is the ideal statin for polymedicated patients? / Claudio Borghi, Arrigo FG Cicero // Clin. Lipidol. – 2012. – V. 7. – № 3. – Suppl. 1. – P. 11–16.
Duggan S.T. Pitavastatin: a review of its use in the management of hypercholesterolaemia or mixed dyslipidemia / S.T. Duggan // Drugs. – 2012. – V. 72. – № 4. – Р. 565–584.
ESC/EAS Guidelines for the management of dyslipidemias // European Heart Journal (2011) 32, 1769–1818.
Han K.H. Evaluation of shortterm safety and efficacy of HMGCoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage) / [K.H. Han, S.W. Rha, H.J. Kang et al.] // J. Clin. Lipidol. – 2012. – Vol. 6(4). – P. 340–351.
Inagaki Y. Drugdrug interaction study to assess the effects of multipledose pitavastatin on steady state warfarin in healthy adult volunteers / [Y. Inagaki, T. Hunt, B. Arana et al.] // J. Clin. Pharmacol. – 2011. – Vol. 51(9). – P. 1302–1309.
Jung J.A. Pharmacokinetic interaction between pitavastatin and valsartan: a randomized, open labeled crossover study in healthy male Korean volunteers / [J.A. Jung, Y.H. Noh, S. Jin et al.] // Clin. Ther. – 2012. – Vol. 34(4). – P. 958–965.
Kastelein J.J.P. Pitavastatin: an overview of the LIVES study / J.J.P. Kastelein, M. Braamskamp // Clin. Lipidol. – 2012. – V. 7. – № 3. – Suppl. 1. – P. 25–31.
Kishida K. Effects of pitavastatin on HDL metabolism / K. Kishida // Clin. Lipidol. – 2013. – V. 8(1). – P. 55–68.
Kishida K. Importance of Assessing the Effect of Statins on the Function of HighDensity Lipoproteins on Coronary Plaque / K. Kishida, T. Funahashi, I. Shimomura // Cardiovascular & Haematological Disorders – Drug Targets. – 2012. – Vol. 12. – P. 28–34.
Kotseva K. EURROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries / K. Kotseva, D. Wood, B.G. De // Eur. J. Cardivasc. Prev. Rehabil. – 2009. – Vol. 16. – P. 121–137.
Mao Y. The effect of pitavastatin on blood glucose and its efficacy in diabetic patients with hypercholesterolemia / [Y. Mao, J.M. Yu, F. Zhang et al.] // Zhonghua Nei Ke Za Zhi. – 2012. – Vol. 51(7). – P. 508–512.
Mao Y. Safety and efficacy of pitavastatin in patients with hypercholesterolemia: a multicenter study / [Y. Mao, J.M. Yu, Y.Q. Zhan et al.] // Zhonghua Yi Xue Za Zhi. – 2012. – Vol. 92(14). – P. 968–973.
Masana L. Pitavastatin in cardiometabolic disease: therapeutic profile / L. Masana // Cardiovasc. Diabetol. – 2013. – Vol. 12. – Suppl. 1. – S. 2.
Mukhtar R.Y. Pitavastatin / R.Y. Mukhtar, J. Reid, J.P. Reckless // Int. J. Clin. Pract. – 2005. – Vol. 12. – P. 239–252.
Saito Y. Pitavastatin: an overview / Y. Saito // Atheroscler. – 2011. –Vol. 12. – Suppl. – P. 272–276.
Sasaki J. A 52 week, randomized, openlabel, parallelgroup comparison of the tolerability and effects of pitavastatin and atorvastatin on highdensity lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of lowdensity lipoprotein cholesterol and glucose intolerance / [J. Sasaki, Y. Ikeda, T. Kuribayashi et al.] // Clin. Ther. – 2008. – Vol. 30. – P. 1089–1101.
Stender S. Pitavastatin demonstrates longterm efficacy, safety and tolerability in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia / S. Stender, D. Budinski, N. Hounslow // Eur. J. Prev. Cardiol. – 2013. – Vol. 20(1). – P. 29–39.
Teramoto T. The clinical impact of pitavastatin: comparative studies with other statins on LDL-C and HDL-C / T. Teramoto // Expert opinion on pharmacotherapy. –2012. – V. 13. – № 6. – Р. 859–865.
Teramato T. A Large Scale Survey on Cardio Cerebrovascular Events During pitavastatin (LIVALO Tablet) Therapy in Japanese patients with Hypercholesterolemia – LIVALO Effectiveness and Safety Study Extension (LIVES Study Extension) / [T. Teramato, M. Urashima, H. Shimano et al.] // Jpn. Pharmacol. Ther. – 2011. – Vol. 39. – P. 789–803.
Warrington S. Comparison of the pharmacokinetics of pitavastatin by formulation and ethnic group: an open label, single dose, two way crossover pharmacokinetic study in healthy Caucasian and Japanese men / S. Warrington, S. Nagakawa, N. Hounslow // Clin. Drug Investig. – 2011. – Vol. 31(10). – P. 735–743.
Weng T.C. A systematic review and metaanalysis on the therapeutic equivalence of statins / [T.C. Weng, Y.H. Yang, S.J. Em et al.] // J. Clin. Pharm. Ther. – 2010. – Vol. 35. – P. 139–151.
Yokote K. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study) / [K. Yokote, H. Bujo, H. Hanaoka et al.] // Atherosclerosis. – 2008. – Vol. 201(2). – P. 345–352.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
